Home › Companies › HROW
Harrow
Market cap $1.11B 37.5M shares (10-Q, Nov 5, 2026) × $29.52 close Nov 17, 2026
Most recent annual filing: 2026-03-02
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- NATACYN topline4Q 2026NATACYN topline, 4Q 2026, material
- Harrow corporate updateNov 2026Harrow corporate update, Nov 2026, material
- TRIESENCE Ph3 toplineEarly 2027TRIESENCE Ph3 topline, Early 2027, material
- G-MELT NDA filing1H 2027G-MELT NDA filing, 1H 2027, notable
- OPUVIZ commercial launchJan 2027OPUVIZ commercial launch, Jan 2027, routine
- BYQLOVI corporate updateMar 4, 2027BYQLOVI corporate update, Mar 4, 2027, routine
- Harrow notes corporate updateMar 15, 2027Harrow notes corporate update, Mar 15, 2027, routine
- G-MELT FDA approval4Q 2027G-MELT FDA approval, 4Q 2027, material
- Novaliq non-compete divestiture clock corporate~Oct 2027Novaliq non-compete divestiture clock corporate, ~Oct 2027, routine
- TRIESENCE corporate update~Mar 31, 2028TRIESENCE corporate update, ~Mar 31, 2028, routine
- TYRVAYA corporate update~Apr–May 2028TYRVAYA corporate update, ~Apr–May 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (15 active programs)
MELT-400
G-MELT
MELT-300
H-N08
CR-01
YOCHIL
MELT-210
IHEEZO
VEVYE
TYRVAYA
varenicline solution
BYOOVIZ
ranibizumab
TRIESENCE
triamcinolone acetonide
BYQLOVI
clobetasol propionate - Postoperative Ocular Inflammation Approved topical Formosa Pharmaceuticals
OPUVIZ
aflibercept-yszy
VERKAZIA
- Vernal Keratoconjunctivitis Approved topical Santen
NATACYN
natamycin Technology platforms
Capital (as filed)
- Cash
- $75.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$8.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $75.3M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Harrow, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-29 Watch Harrow, Inc. (HROW) — Scientific Deep Dive for VEVYE, IHEEZO, TRIESENCE, G-MELT and Pipeline Products VEVYE is a real share-taker but the stock assumes an H2 ramp the company has never demonstrated, on a balance sheet with minimal equity and high leverage, and the flagship licence conflicts with keeping the TYRVAYA acquisition.
- 2026-10-06 Watch UPDATE: Harrow (HROW) - TYRVAYA Closes, Novaliq Still Missing TYRVAYA closing fixed the price and added Japan royalties but did not resolve the Novaliq non-compete conflict, and Q4 SG&A costs arrive before TYRVAYA revenue; the November 10-Q remains the key test.
- 2026-11-10 Avoid UPDATE: Harrow (HROW) - The Revenue Showed Up. Nothing Else Did. Both pre-stated AVOID triggers were hit: EBITDA guidance was cut by more than half and the 10-Q confirmed Novaliq has not consented to TYRVAYA, with VEVYE licence termination named as a possible consequence, while operating cash flow remains negative and leverage is rising.
- Avoid call · opened Nov 10, 2026 at $30.36 · -2.8% vs XBI -6.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“| IHEEZO (QUELL): Topline data from QUELL, a prospective, randomized, multi-center clinical trial evaluating IHEEZO in patients undergoing intravitreal injections, are expected in the fourth quarter of 2026. | | |”
matched to IHEEZO · topline data -
“| NATACYN ® : The first patients were enrolled in an investigator-initiated clinical study during the second quarter, with topline data expected in the fourth quarter of 2026. | | |”
matched to NATACYN · topline data
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Sep 30, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EX-99.1 CORPORATE PRESENTATION DATED NOVEMBER 2026
- Nov 12, 2026ReleaseHarrow to Participate in Two Investor Conferences in November
- Nov 9, 2026ReleaseHarrow Announces Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateHarrow's Q3 print landed at $99.3M — clearing the bar I set — but management simultaneously slashed the EBITDA guide by roughly 60% and the 10-Q formally confirmed the Novaliq/TYRVAYA conflict remains unresolved, with no consent obtained. The revenue ramp is real; the profit ramp is not what was promised.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseHarrow Launches HarrowRx Platform
- Oct 26, 2026ReleaseHarrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
- Oct 5, 2026ReleaseHarrow Closes Acquisition of TYRVAYA®→ BD updateSummary on the 8-K
- Oct 5, 20268-KCurrent report: material agreement, acquisition / disposition, Reg FD disclosure · EX-99.1→ BD updateHarrow closed the TYRVAYA acquisition this morning for $30M cash — and the closing 8-K contains zero mention of Novaliq, the licensor whose filed contract appears to require Harrow to divest any competing dry-eye prescription product within 12 months of acquisition.
- Sep 30, 2026ReleaseHarrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
- Sep 4, 20268-KCurrent report: officer / director change
- Aug 10, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Aug 10, 202610-QQuarterly report
- Aug 6, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- Jun 22, 20268-KCurrent report: shareholder vote
- Jun 3, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- May 11, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 11, 202610-QQuarterly report
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Mar 27, 20268-KCurrent report: material agreement, debt / obligation, other events
- Mar 24, 20268-KCurrent report: other events · EX-99.1
- Mar 24, 20268-KCurrent report: other events · EX-99.1
- Mar 10, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 2, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Mar 2, 202610-KAnnual report
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)